Milatuzumab hLL1; MEDI-115|cas:899796-83-9|西域试剂

Milatuzumab hLL1; MEDI-115

产品编号：Bellancom-P99731| CAS NO：899796-83-9

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99731	￥3500.00	杭州北京（现货）
Bellancom-P99731	￥9100.00	杭州北京（现货）
Bellancom-P99731	￥14500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Milatuzumab hLL1; MEDI-115

产品介绍

Milatuzumab (hLL1; MEDI-115) 是一种人源化抗 CD74 单克隆抗体。CD74 是一种完整的膜蛋白，与促进 B 细胞生长和存活有关。Milatuzumab 导致自由基氧的产生和线粒体膜电位的丧失。 Milatuzumaba 还降低 CD20/CD74 聚集体和细胞粘附，从而导致细胞死亡。

生物活性

Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death.

体外研究

Milatuzumaba（5 μg/mL；8-48 小时）增强 MCL 细胞系和原发性患者肿瘤细胞的细胞死亡。
Milatuzumaba（5 μg/mL；0.5-2 h）在 Jeko、Mino 和 SP-53 细胞中介导细胞毒性，部分取决于 ROS 的产生和线粒体跨膜电位的丧失。
Milatuzumaba（5 μg/mL；4 小时）抑制 NF-κB 通路并诱导细胞凋亡，凋亡机制与 caspase 裂解、Bcl-2 家族成员失调或诱导自噬无关。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	Jeko and Mino cells
Concentration:	5 μg/mL
Incubation Time:	4 hours
Result:	Insignificant down-regulation of antiapoptotic proteins, such as Bax, Bcl-2, Bcl-xL, and Mcl-1.

Cell Viability Assay

Cell Line:	MCL cell lines and primarypatient tumor cells
Concentration:	5 μg/mL
Incubation Time:	8, 24, and 48 hours
Result:	Resulted in cell death of Jeko, Mino, SP-53, Rec-1, HBL-2, and Granta cells.

Immunofluorescence

Cell Line:	Jeko, Mino, and SP-53 cells
Concentration:	5 μg/mL; with or without 10 mM N-acetylcysteine (HY-B0215) for 1.5 h
Incubation Time:	0.5, 1, 1.5, and 2 hours
Result:	Increased ROS generation as early as 0.5 hours, while peaking at 1 to 1.5 hours and reducing at 2 hours.Therefore, it resulted cell death, but reserved by nonspecific ROS scavenger.

体内研究
(In Vivo)

Milatuzumaba（15 mg/kg/天；腹腔注射；每 3 天一次）显着提高携带 Jeko 癌细胞的雌性 SCID 小鼠的存活率。并且Milatuzumaba与Rituximab (HY-P9913) 在该小鼠模型中具有协同作用。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Jeko mouse model
Dosage:	15 mg/kg/day; with or without 15 mg/kg Rituximab
Administration:	Intraperitoneal injection; once every 3 days, starting at day 15 after engraftment
Result:	Resulted the mean survival for the combination treated group of 44.5 days, compared with 33.5 days for Milatuzumaba treated, 28 days for control.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Jeko mouse model
Dosage:	15 mg/kg/day; with or without 15 mg/kg Rituximab
Administration:	Intraperitoneal injection; once every 3 days, starting at day 15 after engraftment
Result:	Resulted the mean survival for the combination treated group of 44.5 days, compared with 33.5 days for Milatuzumaba treated, 28 days for control.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Jeko mouse model
Dosage:	15 mg/kg/day; with or without 15 mg/kg Rituximab
Administration:	Intraperitoneal injection; once every 3 days, starting at day 15 after engraftment
Result:	Resulted the mean survival for the combination treated group of 44.5 days, compared with 33.5 days for Milatuzumaba treated, 28 days for control.